Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.72 |
| ▸ | CHAT | P28329 | 1/20 | 0.72 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL29360751 | 1.00 | SNCA (0.72) | SNCACHATCDK2TTRFABP4 | |
| Potassium Ion SCHEMBL1082232 | 1.00 | SNCA (0.72) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL30261938 | 0.84 | SNCA (1.00) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL64271 | 0.84 | SNCA (1.00) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL29382721 | 0.84 | SNCA (1.00) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL20574382 | 0.83 | SNCA (0.97) | SNCACHATCDK2TTRFABP4 | |
| Potassium SCHEMBL1082234 | 0.83 | SNCA (0.97) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL2862964 | 0.79 | THRB (0.53) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL591337 | 0.79 | THRB (0.53) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL29353590 | 0.79 | THRB (0.53) | SNCACHATCDK2TTRFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4427033-B1 | METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-4427033-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA Biotech GmbH (DE) | 2024-09-11 | — | — | EP | claimed |
| WO-2023079052-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-2802871-B1 | CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | claimed |
| EP-4427033-B1 | METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2026-05-20 | — | — | EP | disclosed |
| EP-3621945-B1 | STILBENE DERIVATIVES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | AMBIENT PHOTONICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250333472-A1 | Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto | GEORGE MASON RES FOUNDATION INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12331096-B2 | Binding domain mapping and compounds, compositions, complexes, methods, and kits related thereto | George Mason Research Foundation, Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4427033-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA Biotech GmbH (DE) | 2024-09-11 | — | — | EP | disclosed |
| US-12071468-B2 | Purification of Factor VIII subspecies | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-27 | — | — | US | disclosed |
| US-11892449-B2 | Therapeutics and point of care lateral-flow test for virus and antibodies using tagged assembled proteins | NEW YORK UNIVERSITY (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4087860-B1 | COMPOUND AND METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE | ALPHABETA AB (SE) | 2023-11-22 | — | — | EP | disclosed |
| US-20230002458-A1 | COMPOUND AND METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE | ALPHABETA AB (SE) | 2023-01-05 | — | — | US | disclosed |
| EP-4087860-A1 | COMPOUND AND METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE | Alphabeta AB (SE) | 2022-11-16 | — | — | EP | disclosed |
| US-11493518-B2 | Binding domain mapping | George Mason Research Foundation, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220275058-A1 | PURIFICATION OF FACTOR VIII SUBSPECIES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-01 | — | — | US | disclosed |
| WO-2022104088-A2 | METHOD FOR TREATING AMYLOIDOGENIC DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-05-19 | — | — | WO | disclosed |
| US-20220152090-A1 | METHOD FOR TREATING AMYLOIDOGENIC DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-05-19 | — | — | US | disclosed |
| US-11299533-B2 | Purification of factor VIII subspecies | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-04-12 | — | — | US | disclosed |
| US-11286233-B2 | Stilbene derivatives for the treatment of CNS and other disorders | Ambient Photonics, Inc. (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333472-A1 | Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto | SNRPE, SSBP1, RPA1 | SNCA 4163/4885CHAT 4309/4885CDK2 1916/4885 |
| US-11286233-B2 | Stilbene derivatives for the treatment of CNS and other disorders | CLN6, MAPT, PSEN2 | SNCA 17/4885CHAT 100/4885CDK2 1756/4885 |
| US-12331096-B2 | Binding domain mapping and compounds, compositions, complexes, methods, and kits related thereto | SNRPE, SSBP1, RPA1 | SNCA 4163/4885CHAT 4309/4885CDK2 1916/4885 |
| US-11493518-B2 | Binding domain mapping | SNRPE, HSPBP1, CNBP | SNCA 3751/4885CHAT 4801/4885CDK2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.